The month-six plateau: why the scale stops, and the four questions your clinician asks.

The short answer

A GLP-1 plateau in the back half of the first year is not your medication failing; it is the pattern the trials predicted. The published weight curves for both branded semaglutide and branded tirzepatide fall steeply through the first six months, bend through the months that follow, and approach level ground somewhere between month six and the end of year one, which means the stall you are staring at is, statistically speaking, right on schedule.

I have this conversation most weeks, and it follows the same arc every time: first the evidence that this is normal, then the four questions I actually ask before anyone's dose changes. This article is that conversation, written down.

What the trial curves look like after month six

Every major trial of these medications publishes a time-course figure, average weight over the weeks of the study, and they rhyme. In the 68-week trial behind the branded semaglutide 2.4 mg weight label, the average participant lost weight fastest in the opening months, more slowly through the middle, and finished the study at 14.9 percent below baseline with a curve visibly flattening toward the end. The 72-week trial behind branded tirzepatide's label shows the same shape ending lower, an average 20.9 percent reduction at the highest dose, and the label's longer figures, which run out toward week 88, show the line going essentially level in the second year.

Read those curves honestly and the message is not subtle. The steep season is the first half year. The bend is the second. Nobody's average line falls forever, and the trials that produced the best numbers in the history of weight medication all end in a plateau. Those figures describe branded, FDA-approved products, not compounded preparations, and averages rather than individuals, but the shape is the physiology talking, and the physiology is universal.

So the first thing a month-six stall means is: you have caught up to the curve. The results timeline covers the full arc; what follows here is what a clinician does at the bend.

Set point, adaptation, and why this is expected

Why does the curve bend? Because your body is not a passive account that medication debits. It defends itself.

As weight falls, energy expenditure falls with it, partly because a smaller body simply costs less to run, and partly through what researchers call metabolic adaptation, an additional dialing-down beyond what the new size predicts. Hunger hormones shift in the direction of regain; the appetite quieting you felt at the start is now working against a stronger current. At some point the medication's push and the body's pushback reach equilibrium, and equilibrium is precisely what a plateau is. This tug-of-war around a defended set point is the standing explanation in the obesity literature for why the trial curves flatten rather than fall indefinitely.

Two reframes follow, and I use both in clinic. First, a GLP-1 plateau is evidence the medication is holding ground against that current; stop it, and the trials of discontinuation show the current wins, a story we tell fully in what happens when you stop. Second, maintenance is not the absence of progress. It is the harder half of the sport, and arriving there is not the moment to quit; it may be the moment the quarterly rhythm with a clinician matters most.

That said, not every stall at month six is the physiologic plateau. That is what the four questions are for.

Question one: dose

The first question is the obvious one: is there ladder left, and is climbing it wise?

The dose charts have a defined top, 2.4 mg for branded semaglutide, 15 mg for branded tirzepatide, and a defined logic short of the top, maintenance chosen by response and tolerability. If you plateaued at a middle rung, a step up after at least four weeks settled is the textbook response, and the trials' dose-response data say the higher rungs carry real additional effect on average. If you are already at or near the ceiling, the conversation is different, tuning expectations, protecting the result, or, where appropriate, considering the other molecule, whose head-to-head averages run higher.

But dose is a question, not a reflex, and I ask it first mostly to get it out of the way, because the next three questions move the scale more often than people expect. The full ladder, and why the lowest holding dose is the right one, lives in the dose chart explainer.

Question two: protein and resistance training

The second question: what is the weight that stopped moving actually made of?

Lose weight fast with a quieted appetite and some of what leaves is lean mass, unless protein and resistance work argue otherwise. By month six, undereating protein has a signature: strength down, energy flat, and a scale that stalls while clothes still loosen, because body composition keeps changing after raw weight pauses. The countermove is unglamorous and effective: protein at every meal, first on the plate, and two or three sessions a week of resistance training, which is the single strongest signal you can send that the remaining weight should come from fat. Our guides to protein on a GLP-1 and strength training during treatment turn this into numbers and routines.

There is also a measurement honesty check inside this question. A tape measure, a monthly photo, and how a specific pair of jeans fits are all plateau detectors that a bathroom scale is blind to. More than once I have watched a plateau dissolve under better measurement without a single change to the protocol.

If we do decide composition is the issue, the fix has a timeline worth respecting: protein and resistance work change body composition over months, not weeks, and the scale is the last instrument to notice. I ask members starting this correction to commit to eight weeks before rendering a verdict, and to let strength numbers, how the third set feels, whether the grocery bags got lighter, serve as the early scoreboard. Muscle you keep is metabolism you keep, which is exactly the currency a plateau negotiation is conducted in.

Question three: sleep and stress

The third question surprises people: how are you sleeping, and what is your season of life doing to you?

Short sleep and unmanaged stress push appetite hormones the wrong way, raise the pull of exactly the foods a slowed stomach handles worst, and quietly add back the evening calories the medication had removed. Cortisol's fingerprints on weight are real, and a month of five-hour nights can flatten a curve all by itself. On top of appetite, fatigue erodes the training from question two, and the whole system loses its margin. We wrote about the sleep and cortisol connection at length; the plateau-clinic version is one sentence: I do not adjust a dose to solve a sleep problem until we have at least named the sleep problem.

The practical audit is short. Bedtime and waketime for a typical week, caffeine after noon, alcohol in the evenings, and what the hardest hour of the day looks like. Fixes here are slow but compound, and they cost nothing at the pharmacy.

Alcohol deserves one more sentence inside this question, because it touches all three of the others at once: it carries calories that bypass appetite signaling, it degrades exactly the deep sleep that regulates hunger hormones, and an evening pour is usually stress management wearing a costume. Nobody at Parke moralizes a drink, but a member staring at a six-week stall who also describes nightly wine has, at minimum, an experiment worth running for a month before any prescription changes.

Question four: the calendar, and patience

The last question is the one the first three earn: how long has the stall actually lasted, at a truly stable dose, measured properly?

Weight is noisy. Water, salt, hormones, travel, and a weekend all move the number by more than a real week of fat change, so two flat weeks is weather, not climate. My working definition of a plateau worth acting on is four to six weeks of no trend at a settled dose with the boring things above in order, essentially the same standard we apply at week twelve, applied to a later season. Inside that window, the right prescription is often the calendar itself.

And if it is a true plateau, at ceiling dose, with composition, sleep, and measurement all honest? Then we say the quiet thing plainly: this may be the result, and it is usually a result worth defending. The trials' plateaus are not tragedies; they sit at double-digit percentages below baseline, in territory obesity medicine could not reach a decade ago. Maintenance, done deliberately, is the victory condition, not the consolation prize.

“A plateau at month six is the curve doing what every published curve does. My job is to find the ten percent of cases where it is something else.”

Dr. Marcus Okafor, MD

The bottom line

The GLP-1 plateau between month six and month twelve is written into every trial curve these medications have produced: steep, then bending, then level, at averages of 14.9 and 20.9 percent below baseline for the branded products at their studied doses. When the scale stops, the clinician's sequence is four questions, dose, composition and protein, sleep and stress, and the honest calendar, and only one of the four ends in a prescription change. All of the numbers above come from branded, FDA-approved products, not compounded preparations, and none of them are promises.

If your plateau needs the four questions asked by someone who can act on the answers, that is precisely the visit-free medicine Parke runs: tirzepatide and semaglutide with a clinician reading your protocol at every refill, and eligibility takes about two minutes.

The GLP-1 plateau: frequently asked questions

Is it normal to plateau on semaglutide after 6 months?

Yes. The time-course curves in the branded semaglutide trials fall steeply through the first months and visibly flatten in the back half of the first year, ending near 14.9 percent below baseline on average in the 68-week trial. A stall in that window usually means you have met the curve, not that the medication quit. Confirm it over four to six weeks before acting.

Does a plateau mean I need a higher dose?

Sometimes, and it is the first question a clinician checks, but not the reflex answer. If you sit at a middle rung, a step up is standard; at the ceiling, the levers are protein, resistance training, sleep, measurement, and occasionally a molecule switch. Dose changes follow only after the stall survives an honest four-to-six-week look at a stable dose.

How long does a GLP-1 plateau last?

No label or trial publishes a plateau-duration figure, so beware anyone quoting one. Practically, stalls from water, stress, sleep, or travel resolve within weeks; the physiologic plateau at the curve's end is not a pause but an equilibrium, and the goal shifts to holding it. Your clinician's four questions distinguish the two, which is why the timeline belongs in a message, not a guess.

This article is general education, not medical advice, and it is not a complete list of risks or side effects. Trial figures cited here come from studies of branded, FDA-approved products; compounded medications are prepared by state-licensed US compounding pharmacies and are not FDA-approved or evaluated for safety, effectiveness, or quality. Whether any treatment is appropriate for you is a decision made with a licensed clinician who knows your history. If you are experiencing a medical emergency, call 911. Review the important safety information on each treatment page.